Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: A phase I trial

Gene Therapy

Volumn 8, Issue 4, 2001, Pages 308-315

  Mulvihill, S ^a   Warren, R ^a   Venook, A ^a   Adler, A ^a   Randlev, B ^b   Heise, C ^b   Kirn, D ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ONYX PHARMACEUTICALS   (United States)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Adenovirus; Oncolytic virus; Pancreatic cancer; Phase I clinical trial; Replication selective

Indexed keywords

ANTINEOPLASTIC AGENT; CD4 ANTIGEN; NEUTRALIZING ANTIBODY; ONYX 015; PROTEIN P53; THROMBOPLASTIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADENOVIRUS; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD; CANCER RADIOTHERAPY; CANCER SURGERY; CELL COUNT; CELLULAR IMMUNITY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLYSIS; DOSE RESPONSE; DRUG DETERMINATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; FEVER; GASTROINTESTINAL DISEASE; GENE DELETION; GENE FUNCTION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPERSENSITIVITY REACTION; JAUNDICE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PAIN; PANCREAS CARCINOMA; PANCREATITIS; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN TEST; SWEATING; TUMOR CELL; TUMOR GROWTH; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1B PROTEINS; ADULT; AGED; CANCER VACCINES; CARCINOMA; FEASIBILITY STUDIES; FEMALE; GENE DELETION; GENE THERAPY; GENES, P53; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; MUTATION; PANCREATIC NEOPLASMS; VIRUS REPLICATION;

ADENOVIRIDAE; DNA VIRUSES; ONYX;

EID: 0035076823     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301398     Document Type: Article

References (27)

1. Cancer of the pancreas
2. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
3. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer
4. K-ras and p53 mutations in pancreatic cancer: Ductal and non-ductal tumors progress through different genetic lesions
5. Implications of the p53 tumor-suppressor gene in clinical oncology
6. Expression of p16INK4ap16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression
7. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways
8. p53 mutation and MDM2 amplification in human soft tissue sarcomas
9. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy
10. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
11. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
12. Intravenous administration of ONYX-015, a selectively-replicating adenovirus, induces antitumoral efficacy
13. A phase II trial of intratumoral injection with an E1B-deleted adenovirus, ONYX-015, in patients with recurrent, refractory head and neck cancer
14. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
15. Hepatic arterial infusion of a replication-selective adenovirus. Onyx-015: A phase I/II clinical trial
16. A controlled clinical trial of intratumoral Onyx-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
17. A phase I clinical trial with ONYX-015 (a selectively replicating adenovirus) administered by intratumoral injection in patients with recurrent head and neck cancer
18. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver
19. Regulation of TNF-mediated cell death and inflammation by human adenoviruses
20. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis
21. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia
22. Role of early genes in pathogenesis of adenovirus pneumonia (published erratum appears in Proc Natl Acad Sci USA 1991; 88: 681)
23. Role of early region 3 (E3) in pathogeneis of adenovirus disease
24. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: Intratumoral spread and distribution effects
25. A phase I study of multiple direct injections of ONYX-015 adenovirus under endoscopic ultrasound guidance
26. Replication-selective micro-organisms: Fighting cancer with targeted germ warfare
27. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection